Background {#s1}
==========

Botulism is a rare disease occurring worldwide and is caused by botulinum toxin made by Clostridium botulinum bacteria. This disease is hard to control due to the emergence of drug-resistant pathogenic strains. Present treatment use antitoxin, which can target the neurotoxin at the extracellular level, however, can\'t converse the paralysis caused by botulism. To combat the current state, discovery of new drug targets is needed, which is known as the first step in the drug discovery process \[[@R01]\]. Traditional methods of drug target identifications are time consuming and overpriced, which cannot fight effectively against the rapidly growing multidrug-resistant bacteria. The success of human genome project as well as sequencing of many pathogenic bacteria has provided sufficient data that can be used to predict drug and vaccines targets using in-Silico approach \[[@R02], [@R03]\]. A subtractive genomics method along with Bioinformatics analysis is widely used approach for the drug target prediction \[[@R04]\]. This has open new routes for the identification of potential therapeutic candidates, which has accelerated the drug discovery process, maximizes the treatment alternatives and reduced the drug failure rate in the later phase of clinical trials saving lots of money. In the last decades, a subtractive genomics approach has been effectively used to predict drug targets in Pseudomonas aeruginosa \[[@R05]\], Mycobacterium tuberculosis \[[@R06]\], and Salmonella enterica \[[@R07]\]. The similar subtractive genomic approach has adopted in this study to predict potential drug and vaccine targets in C. botulinum, where pathogen-specific, essential proteins were mined from the analysis of chokepoint, pathway, plasmid, virulence and resistance proteins. Moreover, the subtraction dataset between the host and the pathogen genome offers a set of genes that are likely to be important to the pathogen but absent in the host. The identified pathogen-specific proteins have the potential to become a good target and might be used in the drug discovery process.

Methodology {#s2}
===========

The probable drug targets in C. botulinum (strain Hall/ ATCC 3502/ NCTC 13319/ Type A) was identified through the subtractive genomics approach, including I) mining of essential proteins, II) subtractive analysis to exclude human homologs and III) qualitative characterization of probable targets essential for the growth of C. botulinum. A flowchart of the method used in this study is given in [Figure 1.](#F1){ref-type="fig"}

Stage I: {#s2a}
========

Mining of essential proteins The mining of essential proteins included the following analysis.

Chokepoint proteins (CP): {#s2b}
=========================

Chokepoint proteins (enzymes) from C. botulinum and human host (labeled with A) were identified individually using Chokepoint Reaction Finder of BioCyc database \[[@R08]\]. The identical CP between human and C. botulinum was disqualified to avoid cross targeting and CP unique to C. botulinum (labeled with A1) was retained for further analysis. These proteins were further confined by their related enzymatic reactions (labeled with A2) in the KEGG database \[[@R09]\].

Plasmid proteins: {#s2c}
=================

Plasmid proteins of C. botulinum (labeled with B) were retrieved using NCBI \[[@R10]\].

Pathway proteins: {#s2d}
=================

Metabolic pathways in C. botulinum and human host (labeled with C) were obtained independently from the KEGG database \[[@R09]\] and subsequently compared to identify proteins present in distinct pathways of pathogens (labeled with C1) and shared pathways of pathogen and host (labeled with C2).

Virulence proteins: {#s2e}
===================

Virulence factors formerly reported from C. botulinum A str. ATCC 3502 (serotype A) was retrieved from the Virulence Factors Database (VFDB) \[[@R11]\] and scientific literature (labeled with D1). These proteins were manually examined for their existence in human pathways and proteins missing in the host were selected (labeled with D2).

Resistance genes and protein network: {#s2f}
=====================================

Orthologs of antibiotic resistance genes (such as gyrA, gyrB, rpoB, tetM and catD) in C. botulinum was obtained from the NCBI (labeled with E). The high confidence interactors (STRING score \> 0.9) for resistance protein in C. botulinum were observed through STRING 10.0 \[[@R12]\] and the interactors absent in human pathways (labeled with E1) was selected for further analysis.

Stage II: Subtractive channel of analysis {#s2g}
=========================================

The collected proteins (labeled with A-E) were aligned with each other, and the projected unique proteins were passed through a series of subtractive analysis to predict possible drug targets in C. botulinum.

Human non-homology analysis: {#s2h}
============================

Proteins that are non-homologous to human (labeled with F) were filtered using BLASTp search against the non-redundant database of H. sapiens with E-value of 0.005.

Essentiality analysis: {#s2i}
======================

The identified non-homologous proteins were searched against the Database of Essential Genes (DEG) \[[@R13]\] with E-value of \<0.0001 and the significant hits were retained (labeled with G).

Anti-target non-homology analysis: {#s2j}
==================================

The identified essential proteins were filtered against the antitargets (essential proteins) of a host (n=210) with E-value of 0.005. The non-homolog proteins in the analysis were retained (labeled with H).

Gut flora non-homology analysis: {#s2k}
================================

The identified anti-targets were filtered against the proteins of human gut microbiota (n=66) using BLASTp with E-value of \<0.0001 and sequence pairs with \<50%. The shortlisted targets (labeled with I) were retained for qualitative characterization in stage III.

Stage III: {#s2l}
==========

Qualitative characterization of the shortlisted targets The shortlisted targets (labeled with I) were characterized through cellular localization, broad spectrum, interactome, functionality, and druggability analysis.

Cellular localization analysis: {#s2m}
===============================

Finding the protein location is significant to predict possible vaccine antigen candidates (surface proteins) and probable drug candidates (inner membrane and cytoplasmic proteins) in bacteria. The location of the shortlisted targets was predicted using Uniprot \[[@R14]\], CELLO \[[@R15]\], Gpos-mPLoc \[[@R16]\] and PSORTb \[[@R17]\].

Broad-spectrum target analysis: {#s2n}
===============================

BLASTp search against the pathogenic strains (n=223) with an expected threshold value of 0.005 were performed to predict broadspectrum targets in C. botulinum. The shortlisted candidates were further mapped to Cluster of Orthologous Groups of proteins (COG) \[[@R18]\] resulting homologs in other pathogenic bacteria.

Interactome analysis: {#s2o}
=====================

PPI network was constructed for the shortlisted targets using STRING 10.0 \[[@R12]\] and interactions with a STRING score \> 0.9 were analyzed using Cytoscape 2.8.1 \[[@R32]\]. The targets (proteins) with a high degree or number of connections it has to other nodes were termed as \'hub\' genes \[[@R19]\] and considered as probable drug candidates.

Functionality analysis: {#s2p}
=======================

The function of the hypothetical proteins from the list of shortlisted targets was predicted using INTERPROSCAN \[[@R33]\].

Druggability analysis: {#s2q}
======================

Druggability of the shortlisted targets was analyzed using BLASTp search against the DrugBank 3.0 \[[@R20]\] with an e-value of 10^-5^. This is crucial to identify targets tested by FDA approved drugs. Targets non-homologous to the targets of the DrugBank were labeled as \'novel\' targets.

Results and discussion: {#s3}
=======================

Chokepoint protein (CP): {#s3a}
------------------------

A total of 810 chokepoint reactions, including producing (325), consuming (305), and concurrently producing and consuming (180) from C. botulinum were generated ([Table 1](#T1){ref-type="table"}). The identical CP between human and C. botulinum was excluded which revealed 640 CP proteins unique to C. botulinum. It\'s an important step to avoid adverse health effects, as the possible drug may also target host\'s CP enzymes. Out of 640, enzymatic reactions of 295 were observed in the KEGG pathway. The protein catalyzing CP reaction is considered as a highly ranked metabolic drug target \[[@R21]\].

Plasmid protein: {#s3b}
----------------

A total of 18 plasmid proteins from C. botulinum were retrieved using the NCBI databases ([Table 1](#T1){ref-type="table"}). Plasmids might play a key role in the adaptability of microbes by providing antibiotic resistance against a wide range of antibiotics and hence be a valuable drug target \[[@R22]\].

Pathway protein: {#s3c}
----------------

A comparative metabolic pathway analysis of H. sapiens (280 pathways) and C. botulinum (92 pathways) revealed 23 distinct (present in C. botulinum and absent in H. sapiens) and 59 shared (present in both host and pathogen) pathways ([Table 1](#T1){ref-type="table"}). The associated proteins from distinct (325) and shared pathways (906) were further collected and the proteins common to C. botulinum and human host pathway were omitted to avoid cross targeting in this study. This approach includes the targeting of many specific highpriority pathways for the expansion of multi-drug resistance among pathogenic bacteria \[[@R23]\].

Virulence proteins: {#s3d}
-------------------

A total of 36 virulence proteins from Virulence Factors Database (9), literature (16), and proteolytic group I (11), associated with pathogenicity \[[@R24]\] were collected and excluding the repeats, 33 unique proteins absent in human pathways were selected ([Table 1](#T1){ref-type="table"}). Virulence factors expressed through bacteria are vital for the survival and growth of pathogenic bacteria and hence can be a valuable drug targets.

Resistance genes and protein network: {#s3e}
-------------------------------------

Network analysis disclosed 107, 78, 33, and 30 associated interactors for orthologs of rpoB, tetM, gyrA, gyrB antibiotic resistance genes, respectively. Next, a total of 152 interactors absent in human pathways were selected which can be a good target ([Table 1](#T1){ref-type="table"}). In this study, no interactors were observed for catD resistance genes.

Subtractive channel of analysis Human non-homologous: {#s3f}
-----------------------------------------------------

Potential drug targets homologous to host could harmfully affect the host metabolism. Thus, avoiding proteins homologous to host is considered as the leading step in the identification of good drug targets \[[@R25]\]. In this study, qualified datasets from chokepoint protein, plasmid protein, pathway protein, virulence factors, and resistance gene analysis were subjected to non-homology analysis. A total of 1729 proteins were used for homology search and 893 non-homologous proteins were selected ([Table 1](#T1){ref-type="table"}).

Essentiality: {#s3g}
-------------

The potential drug target must be a crucial protein for the survival of the pathogen \[[@R25]\].Out of 893 non-homologous proteins, 633 proteins were aligned significantly to Database of Essential Genes (DEG) and were considered as essential proteins for the survival of the pathogen ([Table 1](#T1){ref-type="table"}). The non-aligned 260 proteins were excluded from this analysis.

Anti-target non-homologous: {#s3h}
---------------------------

Protein non-homologous to anti-targets (human essential proteins) is endorsed as drugs inhibiting such targets may interfere with host metabolism triggering severe toxic effects in the host \[[@R26]\]. In this analysis, 633 essential proteins were undergoing a homology search and homologous proteins with anti-target of the host were eliminated, whereas 483 non-homologous proteins were retained for further analysis ([Table 1](#T1){ref-type="table"}).

Gut flora non-homologous: {#s3i}
-------------------------

The human host co-evolved with a gut microflora that plays an important role in the absorption of poorly digestible dietary components, vitamin synthesis, and degradation of xenobiotics \[[@R27], [@R28]\]. Gut microbiota also play a key role in human health by providing resistance to colonization of pathogens and opportunistic bacteria \[[@R28],[@R29]\]. Therefore, deterioration of the gastrointestinal microbiota population may lack of first line of defense against invading bacteria and may also deal with the deficiency of nutrients in the host \[[@R28]\]. Anti-target non-homologous 483 proteins were undergoing a homology search and 18 gut flora non-homologous proteins were separated. Finally 15 potential targets were shortlisted after removing the redundancy ([Table 1](#T1){ref-type="table"} and [Table 2](#T2){ref-type="table"}).

Qualitative characterization of the potential drug targets: {#s3j}
-----------------------------------------------------------

Cellular localization:

In this study, we observed the cellular localization of proteins in cytoplasm (6 proteins), membrane (5 proteins), outer membranebounded periplasmic space (3 proteins) and extracellular (1 protein). Proteins that are located in the cytoplasm could be used as drug targets, whereas extracellular and membrane bound proteins are appropriate for vaccine targets \[[@R30]\].

Broad spectrum: {#s3k}
---------------

Alignment of proposed targets with medically vital myco bacterial species and other bacterial pathogens facilitates the assessment of broad-spectrum antibiotics that attack a wide range of bacteria. The shortlisted targets were exposed to Cluster of Orthologous Groups of proteins (COG) hunt to identify homologs in other pathogenic bacteria and we observed four targets homologous to more than 75 pathogens and hence are considered as broad spectrum candidates.

Interactome analysis: {#s3l}
---------------------

A total 14 shortlisted targets were found to be interacting with different C. botulinum strains and protein CBO0881 has maximum 50 interactors. Target with higher interactors was considered as metabolically important active protein, and hence could be used as good drug target \[[@R31]\].

Functionality analysis: {#s3m}
-----------------------

We did not observe any hypothetical proteins from the list of shortlisted targets and hence this step was excluded from this study.

Druggability analysis: {#s3n}
----------------------

The druggability of the proposed targets was evaluated by sequence similarity search against the targets from DrugBank \[[@R20]\] ([Table 3](#T3){ref-type="table"}). Drug target, CBO2715 is found to be homologous with DrugBank targets P26394, Q9HU21, O06330 and O52806 with their corresponding drugs DB02549, DB01694, DB04530 and DB01643, respectively. Remaining drug targets with no homology were differentiated as novel targets ([Table 1](#T1){ref-type="table"} and [Table 3](#T3){ref-type="table"}), which require further experimental validation.

Conclusion {#s4}
==========

In this study, we identified new targets, including drug and vaccine in C. botulinum using subtractive genomic approach. Identified targets were initially confirmed for their role in the survival of the C. botulinum. The downstream analysis includes non-similarity to gut flora proteins, and anti-targets in the host to predict highconfidence drug targets. Proposed targets were found to be an ideal broad-spectrum candidate, whereas interactome analysis highlighted the functional importance of many query targets. The adopted approach has the potential to be used as a general method for target identification and hence the proposed 15 targets might be used in drug discovery program.
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###### : Drug target identification using subtractive genomics approach. The 15 potential targets including drug (6) and vaccine (9) candidates, non-similar to human, gut microflora, and anti-targets in the host were predicted in C. botulinum.

  Drug target using subtractive genomics                                                                                                                                                                                                                                                                                              
  -------------------------------------------------------- -------------------------------------------------- ------------------------------------------- --------------------------------------------- ------------------------------------------------------ ---------------------------------------------------------------------- --------------------------------------------
                                                           Chokepoint (CP) \[A\]                                                                          Excluding repeats                             Against Hsa (CP) \[A1\]                                                                                                       CP reaction in KEGG \[A2\]
  Mining of essential proteins                             810 Cbo proteins                                                                               726 Cbo proteins                              640 Cbo proteins                                                                                                              295 Cbo proteins
  (Stage-I)                                                Producer-325                                                                                   Producer-300                                  Producer-294                                                                                                                  Producer-131
                                                           Consumer-305                                                                                   Consumer-269                                  Consumer-194                                                                                                                  Consumer-106
                                                           Simultaneous-180                                                                               Simultaneous-157                              Simultaneous-152                                                                                                              Simultaneous-158
                                                           Plasmid protein \[B\]                                                                                                                                                                                                                                                      
                                                           18 proteins                                                                                    18 proteins                                                                                                                                                                 
                                                           Pathway protein \[C\]                                                                          Distinct pathways of Cbo against Hsa \[C1\]   Common pathways between Cbo and Has \[C2\]                                                                                    
                                                           92 Cbo pathways                                                                                Pathway- 23                                   Pathway- 59                                                                                                                   
                                                           280 Hsa Pathways                                                                               Proteins-325                                  Proteins-906                                                                                                                  
                                                           Virulence factors (VFD) \[D1\]                                                                                                               Unique proteins absent in human pathways \[D2\]                                                                               
                                                           36 Cbo proteins                                                                                                                              33 Cbo proteins                                                                                                               
                                                           VFD- 9 proteins                                                                                                                              VFD-9 proteins                                                                                                                
                                                           VFD literature-16 proteins                                                                                                                   VFD literature-16 proteins                                                                                                    
                                                           VFD literature Group I (proteolytic)-11 proteins                                                                                             VFD literature with Group I (proteolytic)-8 proteins                                                                          
                                                           Resistance genes and protein network \[E\]                                                                                                   Unique interactors absent in human pathways \[E1\]                                                                            
                                                           Resistance genes-5                                                                                                                           Resistance genes-5                                                                                                            
                                                           Interactors-253 proteins                                                                                                                     Interactors-152 proteins                                                                                                      
  Subtractive Channel of Analysis                          Chokepoint protein                                                                             Plasmid protein                               Pathway protein                                        Virulence protein                                                      Resistance gene and proteins network
  (Stage-II)                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                      
  Input proteins                                           295 proteins                                                                                   18 proteins                                   1231 proteins                                          33 proteins                                                            152 proteins
                                                                                                                                                                                                                                                                                                                                      
                                                           Proteins passed-240                                                                            Proteins passed- 17                           Proteins passed - 547                                  Proteins passed- 28                                                    Proteins passed- 61
  Human non-homology \[F\]                                 Excluded - 55                                                                                  Excluded-1                                    Excluded- 684                                          Excluded-5                                                             Excluded- 91
                                                                                                                                                                                                                                                                                                                                      
  Essentiality \[G\]                                       Proteins passed-199                                                                            Proteins passed- 4                            Proteins passed - 371                                  Proteins passed- 5                                                     Proteins passed -54
                                                           Excluded - 41                                                                                  Excluded-13                                   Excluded - 176                                         Excluded - 23                                                          Excluded - 7
                                                                                                                                                                                                                                                                                                                                      
  Anti-target non-homology \[H\]                           Proteins passed -100                                                                           Proteins passed- 4                            Proteins passed- 320                                   Proteins passed- 5                                                     Proteins passed- 54
                                                           Excluded - 0                                                                                   Excluded-0                                    Excluded- 2                                            Excluded- 0                                                            Excluded- 0
                                                           Repeats excluded-99                                                                                                                          Repeats excluded -49                                                                                                          
  Gut flora non-homology \[I\]                             Proteins passed- 5                                                                             Proteins passed-3                             Proteins passed-9                                      Proteins passed-0                                                      Proteins passed-1
                                                           Excluded - 94                                                                                  Excluded- 1                                   Excluded- 311                                          Excluded- 5                                                            Excluded- 52
                                                                                                                                                                                                                                                                                                                                      Cbo homolog failed subtractive analysis -1
  Excluding repeats                                        Σ15 potential targets found                                                                                                                                                                                                                                                
  Qualitative characterization of 15 targets (Stage-III)                                                                                                                                                                                                                                                                              
  Cellular localization \[J\]                                                                                 Broad spectrum target \[K\]                                                               Interactome \[L\]                                      Functionality \[M\]                                                    Druggability \[N\]
  Cytoplasmic - 6                                                                                             Alignment against the pathogenic strains:                                                 Interactome-14 proteins                                Hypothetical proteins were not observed hence excluded this analysis   Druggable - 1
  Membrane - 5                                                                                                Homolog \>50 = 4                                                                          No Interactome-1 protein                                                                                                      Novel - 14
  Outer membrane-bounded periplasmic space - 3                                                                Homolog \<50 = 11                                                                                                                                                                                                       
  Extracellular - 1                                                                                                                                                                                                                                                                                                                   

###### Functional annotation of potential drug target and vaccine candidates in C. botulinum

  No.   KEGG-ID   Associated pathway   Length (aa)   Description                                                    Uniprot ID   CP Protein   \*COG-ID
  ----- --------- -------------------- ------------- -------------------------------------------------------------- ------------ ------------ ---------------
  1     CBO0703   \-                   278           AraC family transcriptional regulator                          A5HZP6       No           COG2207\[K\]
  2     CBOP005   \-                   181           site-specific recombinase                                      A5I825       No           COG0582\[LX\]
  3     CBOP15    \-                   430           putative bacteriocin biosynthesis protein                      A5I835       No           COG0535\[R\]
  4     CBOP17    \-                   391           TldD family protein                                            A5I837       No           COG0312\[R\]
  5     CBO0311   cbo02010             342           iron compound ABC transporter permease                         A5HYK4       No           COG0609\[P\]
  6     CBO0385   cbo02010             290           phosphate ABC transporter permease                             A5HYS9       No           COG0573\[P\]
  7     CBO0962   cbo02010             260           molybdenum ABC transporter permease                            A5I0F5       No           COG0555\[P\]
  8     CBO1150   cbo02010             221           ABC transporter permease                                       A5I0Z1       No           COG0765\[E\]
  9     CBO0945   \-                   179           Isochorismatase                                                A5I0D8       Yes          \-
  10    CBO0881   cbo02060             629           PTS system beta-glucoside-specific transporter subunit IIABC   A5I073       Yes          COG1264\[G\]
  11    CBO2715   cbo00521, cbo00523   177           dTDP-4-dehydrorhamnose 3,5-epimerase                           A5I5E9       Yes          COG1898\[M\]
  12    CBO1432   cbo01503             283           N-acetylmuramoyl-L-alanine amidase                             A5I1R2       Yes          COG0860\[M\]
  13    CBO3111   cbo01503             967           N-acetylmuramoyl-L-alanine amidase                             A5I6J2       Yes          COG0860\[M\]
  14    CBO2695   cbo02020, cbo02040   272           Flagellin                                                      A5I5C9       No           COG1344\[N\]
  15    CBO3110   cbo01503             949           N-acetylmuramoyl-L-alanine amidase                             A5I6J1       No           \-

###### Qualitative characterization of the potential drug target and vaccine candidates in C. botulinum. Druggability of the proposed targets disclosed 14 candidates as novel targets.

  No.   KEGG-ID   Cellular localization   Broad spectrum (Number of pathogens homologs)   Interactors   Druggablility
  ----- --------- ----------------------- ----------------------------------------------- ------------- ---------------
  1     CBO0703   Cytoplasmic             14                                              7             Novel
  2     CBOP005   Cytoplasmic             94                                              2             Novel
  3     CBOP15    Cytoplasmic             5                                               3             Novel
  4     CBOP17    Cytoplasmic             78                                              1             Novel
  5     CBO0311   Membrane                47                                              30            Novel
  6     CBO0385   Membrane                4                                               12            Novel
  7     CBO0962   Membrane                32                                              13            Novel
  8     CBO1150   Membrane                49                                              10            Novel
  9     CBO0945   Cytoplasmic             87                                              5             Novel
  10    CBO0881   Membrane                24                                              105           Novel
  11    CBO2715   Cytoplasmic             1                                               25            Druggable
  12    CBO1432   \*\*OMBPS               25                                              7             Novel
  13    CBO3111   \*\*OMBPS               25                                              7             Novel
  14    CBO2695   Extracellular           85                                              23            Novel
  15    CBO3110   \*\*OMBPS               27                                              NIL           Novel

![Flowchart describing the comprehensive methodology for the identification of potential targets, including drug and vaccine using subtractive genomics approach.](97320630015018F1){#F1}
